TrippBio Publishes Data Comparing the invitro and in vivo Activity of PanCytoVir™versus Oseltamivir Read More ⟶
TrippBio Submits an Investigational New DrugApplication to the U.S. FDA for PanCytoVir™Treatment of Influenza Read More ⟶
TrippBio Announces Results of a Phase 2 Study of PanCytoVir™ in Patients with Mild-toModerate COVID-19 Read More ⟶
TrippBio Announces Close of Enrollment in the Phase 2 Study of PanCytoVir™ in Patients with Mild-to-Moderate COVID-19 Read More ⟶
TrippBio Announces Initiation of the Phase 2 Study to Evaluate PanCytoVir™ in Patients with Mild-to-Moderate COVID-19 Read More ⟶
TrippBio and University of Georgia Research Foundation Announce Filing of Additional Patent Application Read More ⟶
TrippBio and University of Georgia Research Foundation Expand Licensing Agreement for PanCytoVir™ and Analogs Read More ⟶
TrippBio receives Notice of Allowance from the U.S. Patent Office for Therapeutic Treatment of COVID-19 Infections Read More ⟶
TrippBio announces publication of data supporting the antiviral potency of TD-213 against SARS-CoV-2 Read More ⟶
TrippBio, Inc. announces David E. Martin, PharmD as New President and Chief Executive Officer Read More ⟶
